Baidu
map

NEJM:HIV通用检测及治疗方法可降低30%的感染风险

2019-07-18 MedSci MedSci原创

研究发现,根据当地指导方针,结合预防干预和ART治疗,HIV感染的发生率可降低30%

通用检测和治疗策略是降低人类免疫缺陷病毒(HIV)感染率的一种潜在方法,但目前尚无成熟的通用方法。

在2013-18年进行的HPTN 071(PopART)随机试验中,研究人员随机将赞比亚和南非的21个社区(总人口约100万)分配为A组(综合预防干预与普遍抗逆转录病毒疗法[ART])、B组(根据2016年以来普遍适用的地方指南提供的ART预防干预)或C组(标准护理)。预防干预措施包括社区工作人员提供的基于家庭的艾滋病毒检测、支持与艾滋病护理和ART有关的联系。研究的主要结果是12-36个月之间的艾滋病毒发病率。

48301名参与者。各组的基线HIV感染率为21%-22%。在12-36个月之间,在39702随访年间共观察到553例新的HIV感染(1.4/100人-年;女性,1.7;男性,0.8)。与C组相比,A组调整后的比率为0.93,B组为0.70。A组24个月的HIV阳性患者占71.9%,B组为67.5%,C组为60.2。36个月接受ART治疗的社区HIV阳性成人百分比为81%,B组为80%。

研究发现,根据当地指导方针,结合预防干预和ART治疗,HIV感染的发生率可降低30%。

原始出处:

Richard J. Hayes et al. Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). N Engl J Med, July 18, 2019.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1399276, encodeId=5f3513992e6af, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 20 09:28:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369906, encodeId=8b48369906bb, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 18 21:31:33 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034890, encodeId=cab21034890f2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 18 21:28:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369902, encodeId=4a9536990284, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Thu Jul 18 19:56:47 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1399276, encodeId=5f3513992e6af, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 20 09:28:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369906, encodeId=8b48369906bb, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 18 21:31:33 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034890, encodeId=cab21034890f2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 18 21:28:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369902, encodeId=4a9536990284, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Thu Jul 18 19:56:47 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-18 一个字-牛

    学习了谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1399276, encodeId=5f3513992e6af, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 20 09:28:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369906, encodeId=8b48369906bb, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 18 21:31:33 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034890, encodeId=cab21034890f2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 18 21:28:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369902, encodeId=4a9536990284, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Thu Jul 18 19:56:47 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-18 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1399276, encodeId=5f3513992e6af, content=<a href='/topic/show?id=cac364650c0' target=_blank style='color:#2F92EE;'>#治疗方法#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64650, encryptionId=cac364650c0, topicName=治疗方法)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8cec2200006, createdName=showtest, createdTime=Sat Jul 20 09:28:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369906, encodeId=8b48369906bb, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160304/IMG56D94856B1B5D6405.jpg, createdBy=27931687771, createdName=一个字-牛, createdTime=Thu Jul 18 21:31:33 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1034890, encodeId=cab21034890f2, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 18 21:28:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369902, encodeId=4a9536990284, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Thu Jul 18 19:56:47 CST 2019, time=2019-07-18, status=1, ipAttribution=)]

相关资讯

贺建奎之后,第二名科学家宣布计划制造更多基因编辑婴儿

据《Nature》报道,日前俄罗斯分子生物学家Denis Rebrikov宣布,他将进行基因编辑婴儿试验,如果获得批准的话,年底之前就开始这项计划。如果计划得以实施,他将成为全球公开的第二名进行这一试验的人。

HIV检测“一阴一阳”原因为何?

主要是医生和我们该怎么和患者解释这一结果呢?到底是感染还是没感染呢?与感染科沟通后,建议患者半月后复检。

BMJ:四联抗HIV疗法的疗效不优于三联疗法

研究认为,四联抗逆转录病毒治疗的效果不优于三联疗法,建议采用三联方案作为现行HIV感染的一线治疗手段

NEJM:播散性球孢子菌病-病例报道

该患者开始抗真菌治疗,给予脂质体两性霉素B和氟康唑的组合2周,然后进行氟康唑单一疗法。HIV基因型检测显示患者对服用的一种药物具有抗药性,并且调整了抗逆转录病毒治疗方案。

Nature子刊:基因编辑婴儿死亡风险更高!NEJM中国研究2连发!

除此之外,BMJ还说辣条等过度加工食品会增加心血管风险!快来看看吧!

Lancet HIV:dolutegravir+rilpivirine治疗HIV感染长期疗效显著

研究认为,dolutegravir+rilpivirine疗法表现出持久的HIV抑制效果

Baidu
map
Baidu
map
Baidu
map